Sangamo Therapeutics, Inc. (SGMO) Earnings History
Net Loss27 years of earnings data (1999–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Sangamo Therapeutics, Inc. (SGMO) Earnings Overview
As of June 23, 2026, Sangamo Therapeutics, Inc. (SGMO) reported trailing twelve-month net income of -$123M, reflecting +10.2% year-over-year growth. The company earned $-0.32 per diluted share over the past four quarters, with a net profit margin of -310.8%.
Looking at the long-term picture, SGMO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$4M in fiscal 1999.
Sangamo Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including EDIT (-$109M net income, -395.0% margin), CRSP (-$569M net income, -16569.8% margin), BEAM (-$65M net income, -57.2% margin), SGMO has outperformed on profitability metrics. Compare SGMO vs EDIT →
SGMO Earnings vs Peers
Earnings metrics vs comparable public companies
SGMO Historical Earnings Data (1999–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$123M | -25.5% | -$108M | $-0.44 | -310.8% | -273.1% |
| 2024 | -$98M | +62.0% | -$104M | $-0.49 | -169.4% | -179.9% |
| 2023 | -$258M | -34.1% | -$274M | $-1.48 | -146.3% | -155.5% |
| 2022 | -$192M | -7.8% | -$201M | $-1.25 | -172.8% | -180.8% |
| 2021 | -$178M | -47.3% | -$183M | $-1.23 | -161.1% | -165.6% |
| 2020 | -$121M | -27.1% | -$130M | $-0.90 | -102.4% | -109.6% |
| 2019 | -$95M | -39.3% | -$105M | $-0.68 | -92.9% | -102.7% |
| 2018 | -$68M | -25.2% | -$77M | $-0.70 | -80.9% | -91.4% |
| 2017 | -$55M | +23.8% | -$56M | $-0.70 | -149.2% | -154.1% |
| 2016 | -$72M | -76.1% | -$73M | $-1.02 | -369.6% | -374.2% |
| 2015 | -$41M | -54.1% | -$47M | $-0.58 | -102.9% | -118.5% |
| 2014 | -$26M | +0.8% | -$27M | $-0.39 | -57.6% | -58.4% |
| 2013 | -$27M | -19.6% | -$27M | $-0.48 | -110.3% | -110.7% |
| 2012 | -$22M | +37.7% | -$22M | $-0.42 | -102.8% | -102.5% |
| 2011 | -$36M | -43.8% | -$36M | $-0.71 | -346.4% | -347.1% |
| 2010 | -$25M | -33.7% | -$25M | $-0.55 | -119.5% | -119.9% |
| 2009 | -$19M | +23.5% | -$19M | $-0.44 | -83.8% | -87.4% |
| 2008 | -$24M | -13.1% | -$25M | $-0.60 | -150.1% | -156.8% |
| 2007 | -$21M | -20.2% | -$25M | $-0.58 | -236.1% | -272.3% |
| 2006 | -$18M | -34.4% | -$21M | $-0.55 | -226.6% | -262.9% |
| 2005 | -$13M | +3.8% | -$14M | $-0.51 | -535.1% | -553.5% |
| 2004 | -$14M | -32.4% | -$15M | $-0.55 | -1050.8% | -1114.1% |
| 2003 | -$10M | +64.9% | -$12M | $-0.42 | -404.5% | -456.3% |
| 2002 | -$30M | -17.9% | -$32M | $-1.22 | -685.3% | -726.8% |
| 2001 | -$25M | -178.5% | -$28M | $-1.09 | -516.9% | -582.2% |
| 2000 | -$9M | -138.6% | -$12M | $-0.52 | -264.1% | -363.6% |
| 1999 | -$4M | - | -$4M | $-0.63 | -172.7% | -177.3% |
Download Data
Export SGMO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SGMO — Frequently Asked Questions
Quick answers to the most common questions about buying SGMO stock.
What is SGMO earnings per share (EPS)?
SGMO trailing twelve-month (TTM) diluted EPS is $-0.32, reflecting +10.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1999 to 2025 is available in the table on this page.
What is Sangamo Therapeutics, Inc.'s net income?
Sangamo Therapeutics, Inc. (SGMO) trailing twelve-month net income is $-123M as of 2025. Earnings grew +10.2% year-over-year.
Is SGMO profitable?
SGMO is not currently profitable on a TTM basis, reporting a net loss of $-123M. Net margin is -310.8%. Investors should monitor for a return to profitability.
What is SGMO's earnings growth rate?
SGMO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1999 to 2025.
What are SGMO's profit margins?
Sangamo Therapeutics, Inc. net profit margin is -310.8%, operating margin is -273.1%, and gross margin is +80.8%. Below-average margins reflect competitive or cost pressures. Return on Equity is -2891.8%.
Is SGMO growing earnings?
SGMO is growing earnings steadily. YoY EPS growth of +10.2% is consistent with the 5-year CAGR of N/A. TTM net income is $-123M.
What was SGMO's best earnings year?
Sangamo Therapeutics, Inc.'s highest annual net income on record is $-4M, achieved in fiscal year 1999. Earnings history on this page spans 1999 to 2025 and includes all annual and quarterly figures.
What were SGMO's earnings last quarter?
SGMO's most recent reported quarter was Q1 2026. Net income was $-31M with diluted EPS of $-0.08. For a full breakdown of all quarters, see the quarterly earnings table on this page.